Competitive Technologies reported that researchers at the University of Wisconsin's Carbone Cancer Center have begun accepting patients into a new Phase II clinical study to evaluate the efficacy of the non-invasive Calmare Pain Therapy medical device utilizing versus a sham procedure in treating painful chemotherapy-induced peripheral neuropathy (CIPN).
Competitive Technologies’ Calmare Pain Therapy medical device uses the biophysical Scrambler Therapy technology.
It was developed in Italy by Competitive Technologies’ client professor Giuseppe Marineo.
The Calmare device is currently being manufactured for sale by Competitive Technologies’ partner GEOMC of Seoul, Korea.
The principal investigator for this study is Toby Campbell, a research physician specializing in medical oncology and palliative care at the University of Wisconsin Carbone Cancer Center.
The study is a randomized double-blind, sham-controlled clinical trial with a target enrollment of 40 patients.
The study will measure the effectiveness of the devices by recording the change in participants pain as measured by a Visual Analog Scale (VAS) before and after treatment with the Calmare Scrambler MC-5A device or the sham device.